Abstract:BackgroundThe use of statin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for the treatment of dyslipidemia has been associated with dose limiting hepatoxicity, mytotoxicity and tolerability due to myalgias thereby necessitating the synthesis of new drug candidates for the treatment of lipid disorder.MethodsThe reaction of appropriate benzenesulphonamide with substituted phenoxazinone in the presence of phenylboronic acid gave the targeted compounds. The molecular docking study were carried out using autodock tool against peroxisome proliferator activated receptor alpha. The in vivo lipid profile were assayed using conventional methods. The kidney and liver function test were carried out to assess the effect of the derivatives on the organs. The LD50 of the most active derivatives were determined using mice.ResultsThe targeted compounds were successfully synthesized in excellent yields and characterized using spectroscopic techniques. The results of the molecular docking experiment showed that they were good stimulant of peroxisome proliferator activated receptor alpha. Compound 9f showed activity at Ki of 2.8 nM and binding energy of 12.6 kcal/mol. All the compounds tested reduced triglyceride, total cholesterol, low density lipoprotein cholesterol and very low density lipoprotein cholesterol level in the mice model. Some of the reported compounds also increased high density lipoprotein cholesterol level in the mice. The compounds did not have appreciable effect on the kidney and liver of the mice used. The LD50 showed that the novel compounds have improved toxicity profile.ConclusionThe synthesis of fifteen new derivatives of carboxamides bearing phenoxazinone and sulphonamide were successful. The compounds possessed comparable activity to gemfibrozil. The reported compounds had better toxicity profile than gemfibrozil and could serve as a replacement for the statins and fibrate class of lipid agents.

Oxaprozin prodrug as safer nonsteroidal anti-inflammatory drug: Synthesis and pharmacological evaluation

A review of the emerging profile of the anti-inflammatory drug oxaprozin

Synthetic Strategies Towards Safer NSAIDs Through Prodrug Approach: A Review

Design, synthesis, and in-vivo evaluation of 4,5-diaryloxazole as novel nonsteroidal anti-inflammatory drug

O2-acetoxymethyl-protected diazeniumdiolate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies

Design, Synthesis, Chemical Characterization and In-vivo Screening of Prodrugs

Clinical pharmacokinetics of oxaprozin

Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies

Oxaprozin: kinetic and dynamic profile in the treatment of pain

Anti-Inflammatory and Anticoagulant Activities of Synthesized NSAID Prodrug Esters

Synthesis, biological activities, and pharmacokinetics studies of a mutual prodrug of aceclofenac and paracetamol

Computational Design, Synthesis, and Pharmacological Evaluation of Naproxen-Guaiacol Chimera for Gastro-Sparing Anti-Inflammatory Response by Selective COX2 Inhibition

Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects

Biological Evaluation Of 2-(4-Amino-Phenyl)-3-(3,5-Dihydroxylphenyl) Propenoic Acid

An Enzyme-Responsive Prodrug with Inflammation-Triggered Therapeutic Drug Release Characteristics.

Preparation and Evaluation of Amino Acid Conjugates of Celecoxib as Prodrugs to Improve the Pharmacokinetic and Therapeutic Properties of Celecoxib

Safety profiles of leading nonsteroidal anti-inflammatory drugs

Synthesis and evaluation of azo pro-drugs of flurbiprofen for colon targeting

Novel Phenoxazinones as potent agonist of PPAR-α: design, synthesis, molecular docking and in vivo studies

Oxaprozin: A new hope in the modulation of matrix metalloproteinase 9 activity

Ester Prodrugs of Ketoprofen: Synthesis, Hydrolysis Kinetics and Pharmacological Evaluation